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Background: Associations between serum uric acid (SUA) and changes in
cognitive function are understudied in non-normotensive populations, and
many previous studies only considered the baseline SUA at a single time point.
We aimed to examine the effects of baseline SUA and 4-year changes in SUA
on cognitive changes in the non-normotensive population.
Materials and methods: In the China Health and Retirement Longitudinal
Study (CHARLS), cognitive function was measured based on executive
function and episodic memory in four visits (years: 2011, 2013, 2015, and
2018). We identified two study cohorts from CHARLS. The first cohort included
3,905 non-normotensive participants. Group-based single-trajectory and
multi-trajectory models were applied to identify 7-year cognitive trajectories.
Adjusted ordinal logistics models were performed to assess the association
between baseline SUA and 7-year cognitive trajectories, and subgroup
analyses were conducted according to the presence of hyperuricemia or
SUA levels. The second cohort included 2,077 eligible participants. Multiple
linear regression was used to explore the effect of a 4-year change in SUA on
cognitive change during the subsequent 3-year follow-up.
Results: Four distinct single-trajectories of global cognitive performance
and four multi-trajectories of executive function and episodic memory were
identified. Higher baseline SUA levels were significantly associated with
more favorable cognitive single-trajectories (ORQ4 vs . Q1 : 0.755; 95% CI:
0.643, 0.900) and multi-trajectories (ORQ4 vs . Q1 : 0.784; 95% CI: 0.659,
0.933). Subgroup analyses revealed that the protective effect of SUA was
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significant in the non-hyperuricemia groups or the low-level SUA groups.
Additionally, changes in SUA could influence future cognitive changes.
Compared with non-hyperuricemia participants with elevated SUA, nonhyperuricemia participants with decreased SUA and patients with persistent
hyperuricemia had a higher risk for cognitive decline. Furthermore, only
the Q3 group of changes in SUA could enhance global cognitive function
compared with the Q1 group (β: 0.449; 95% CI: 0.073, 0.826).
Conclusion: Our study indicates that the maintenance of normal SUA levels
and a moderate increase of SUA were advantageous in improving cognitive
function or trajectories in a non-normotensive population. Conversely, SUA
may impair cognitive function in patients with persistent hyperuricemia.
KEYWORDS

cognitive trajectory, cognitive function, serum uric acid, changes in serum uric acid,
hypertension, cohort study

Introduction

the management of hypertension to prevent diabetes, chronic
kidney disease, stroke, and adverse cardiovascular outcomes
(Kawai et al., 2012; Sharaf El Din et al., 2017; Cassano et al., 2020;
Virdis et al., 2020). Hypertension with other chronic diseases
co-occurring in the same individuals may result in a more
severe and accelerated decline in cognitive function (Iadecola
and Gottesman, 2019). Previous epidemiological studies and
meta-analyses found the association of the lower SUA level
with poorer cognitive function and dementia (Wang F. et al.,
2017; Wang T. et al., 2017; Huang et al., 2019; Scheepers
et al., 2019; Chen et al., 2021; Zhou et al., 2021; Huang Y.
et al., 2022), but whether SUA plays a neuroprotective role
among prehypertensive and hypertensive populations remains
unclear. Additionally, the potential protective effects of SUA
on cognition were controversial in other studies. The opposite
association (Beydoun et al., 2016; Suzuki et al., 2016; Latourte
et al., 2018b; Singh and Cleveland, 2018; Alam et al., 2020)
or no association (Richard et al., 2021) between SUA and
cognitive performance have been reported. As for the reason,
most previous studies included participants with hyperuricemia.
Patients with hyperuricemia may have different underlying
etiology pathways due to the impact of higher levels of
SUA on adverse health outcomes as compared to the nonhyperuricemia population (Huang Y. et al., 2022). The different
effects of SUA on cognition among both non-hyperuricemia and
hyperuricemia populations still need further exploration.

Cognitive impairment and dementia have become major
and increasing global health challenges that reduce the quality
of life and cause a huge economic burden (Jia et al., 2018;
Nichols et al., 2019; Davis et al., 2022). Due to the aging
population, the global number of people living with dementia
or cognitive impairment has dramatically increased (Nichols
et al., 2019). Approximately, more than 15% of Chinese older
people are suffering from cognitive impairment (Xue et al.,
2018). Several studies suggested that people with hypertension,
even under prehypertensive conditions, were more likely to
have cognitive decline or dementia (Gottesman et al., 2014;
Chen et al., 2015; Iadecola and Gottesman, 2019; de Menezes
et al., 2021). Considering that there is no effective diseasemodifying treatment for cognitive impairment or dementia (Li
et al., 2020; Davis et al., 2022), early identification of possible
modifiable risk factors of rapid cognitive decline is crucial to
prevent or delay the incidence of cognitive impairment among
the prehypertensive and hypertensive populations.
As a natural antioxidant, serum uric acid (SUA) is thought
to exert a neuroprotective effect by acting as a free radical
scavenger to prevent the development of cognitive dysfunction
(Bowman et al., 2010; Tuven et al., 2017; Kim et al., 2020).
However, urate-lowering therapy plays an important role in

Several other limitations were present in previous studies.
Most previous studies only recorded the SUA levels at baseline,
failing to take into account the potential effect of changes in
SUA in follow-up on subsequent cognitive function (Qiao et al.,
2021). Moreover, these studies neglected the longitudinal change
pattern of cognitive function during the follow-up period.
An advanced statistical method, group-based trajectory models

Abbreviations: SUA, serum uric acid; GBTM, group-based trajectory
model; CHARLS, China Health and Retirement Longitudinal Study; BMI,
body mass index; eGFR, estimated glomerular filtration rate; CMD,
cardiometabolic diseases; SBP, systolic blood pressure; DBP, diastolic
blood pressure; SD, standard deviation; GBMTM, group-based multitrajectory modeling; BIC, Bayesian information criteria; AIC, Akaike
information criterion; APP, average posterior probabilities; CI, confidence
interval; RCS, restricted cubic spline; GEE, generalized estimating
equation; OR, odds ratio.
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4) were enrolled in the study (Supplementary Figure 2). The
timeline of the study is presented in Supplementary Figure 3.

(GBTM), allowed us to identify subgroups that share common
developmental trajectories over time (Nagin and Odgers, 2010).
Thus, the present study was conducted in the nonnormotensive population, including prehypertensive and
hypertensive individuals, to: (1) identify different 7-year
cognitive trajectories and investigate the association between
the baseline SUA levels and cognitive trajectories; (2) assess
the above associations among both the non-hyperuricemia
and hyperuricemia populations; and (3) examine the effect
of 4-year changes in SUA on subsequent 3-year changes in
cognitive performance.

Cognitive function
Cognitive function was assessed by two measures: episodic
memory and executive function according to previous studies
(Lei et al., 2012; Li et al., 2020; Huang Y. et al., 2022). In
the episodic memory test, participants were instructed to recall
words immediately (immediate recall) and 5 min later (delayed
recall) after examiners read 10 Chinese words to them. The
number of correctly recalled words was scored. The episodic
memory score was the average score of the immediate and
delayed recall tests and ranged from 0 to 10 (Hua et al., 2020).
In the executive function test, participants were shown a figure
and asked to redraw it. If the participant succeeded, the score
was 1. They also were asked to subtract 7 from 100 serially five
times and to identify the date (month, day, and year), season,
and day of the week. Answers to these questions were summed
into the executive function score ranging from 0 to 11 (Wu
et al., 2021a). The global cognition score was calculated as the
sum of episodic memory score and executive function score and
ranged from 0 to 21.

Materials and methods
Study population
China Health and Retirement Longitudinal Study
(CHARLS) is a nationwide survey that was conducted among
Chinese adults aged 45 years or older (Zhao et al., 2014), which
is a prospective cohort collecting data on social and economic
information, anthropometric and laboratory measurements,
demographic characteristics, health-related behaviors, and
health conditions. A total of 17,707 participants from 150
county-level units distributed in 28 provinces of China were
recruited at baseline (wave 1: 2011–2012), and the subsequent
three follow-up visits were carried out (wave 2 in 2013, wave 3
in 2015, wave 4 in 2018). Details about the data were previously
described in an earlier publication (Zhao et al., 2014). The
protocols of CHARLS were approved by the Biomedical Ethics
Review Committee of Peking University (IRB00001052-11015).
All participants provided their signed informed consents. We
identified two study cohorts from CHARLS.
The first cohort was constructed to explore the longitudinal
association between baseline SUA and 7-year cognitive
trajectories. Participants were excluded if they had missing
data on gender, age, SUA, and cognitive function; had selfreported the previous diagnosis of brain damage, intellectual
disability, and memory-related disease (Alzheimer’s disease,
brain atrophy, Parkinson’s disease); or were normotensive at
baseline in 2011. Finally, a total of 3,905 participants with two or
more subsequent follow-up visits were enrolled for the analyses
(Supplementary Figure 1).
The second cohort was constructed to examine the effect
of changes in SUA on the future 3-year cognitive changes. We
calculated changes in SUA using the SUA levels in 2011 and
2015 to predict the risk of developing cognitive decline from
2015 to 2018. Participants were excluded if they had missing
data on gender, age, SUA, and cognitive function at baseline or
the survey in 2015; had self-reported the previous diagnosis of
brain damage, intellectual disability, or memory-related disease;
or were normotensive in or before 2015. Ultimately, a total of
2,077 participants who attended the last survey in 2018 (wave
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Measurements of serum uric acid and
serum uric acid changes
Venous blood was collected from participants with their
fasting status recorded. The blood samples were first kept in
local hospitals, then transported to Peking University in Beijing,
and stored at -80◦ C until measurement. The level of SUA was
analyzed using the UA Plus method (Wang T. et al., 2017; Chen
et al., 2019). Hyperuricemia was defined as SUA > 6.0 mg/dL in
women and > 7.0 mg/dL in men (Huang Y. et al., 2022). Sexspecific quartiles of baseline SUA were constructed and used for
subsequent analysis.
Participants were divided into five categories according to
the changes in SUA from baseline in 2011 to the followup survey in 2015: “non-hyperuricemia with elevated
SUA,” “non-hyperuricemia with decreased SUA,” “incident
hyperuricemia,” “remittent hyperuricemia,” and “persistent
hyperuricemia.” “Non-hyperuricemia with elevated SUA”
was defined as hyperuricemia absent both in 2011 and
2015 and an increase in SUA levels. “Non-hyperuricemia
with decreased SUA” was defined as hyperuricemia absent
both in 2011 and 2015 and a decrease in the SUA levels.
Remittent hyperuricemia was defined as hyperuricemia that
was present only in 2011 but not hyperuricemia in 2015.
Incident hyperuricemia was defined as hyperuricemia that
was present only in the follow-up survey in 2015. Persistent
hyperuricemia was defined as hyperuricemia present both
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Ding et al., 2020). Otherwise, they were categorized as
physically inactive.

in 2011 and 2015 (Liu et al., 2018). The first group was
set as the reference group. Then, changes in SUA were
calculated as the SUA level in 2015 minus that in 2011:
Changes in SUA = SUA2015 − SUA2011 .
Both
continuous
and categorical (quartiles) types were constructed and
used in analyses.

Statistical analysis
Baseline characteristics were presented as the mean
(standard deviation, SD), median [interquartile range, IQR], or
number (percentage), as appropriate.
Single trajectories of global cognitive function were
determined using GBTM to map the developmental course of
cognitive performance from the baseline survey to three followup visits. The jointly longitudinal changes in episodic memory
and executive function over time were estimated using groupbased multi-trajectory modeling (GBMTM). GBMTM is a new
application of GBTM and allows the joint modeling of the
trajectories of multiple outcomes (Nagin et al., 2018). GBTM
and GBMTM can identify clusters of individuals following
similar change patterns through multiple visits. Varied models
were considered to choose the optimal number of distinct
groups and trajectory shape parameters (e.g., linear, quadratic,
and cubic) based on Bayesian information criteria (BIC), Akaike
information criterion (AIC), and average posterior probabilities
(APP) of each trajectory group (≥0.70) (Li et al., 2020). In
addition, the sufficient sample size in each trajectory group
(>5% of the sample) and clinical interpretation are important
elements when determining the best model. Finally, trajectories
of cognitive function were plotted over a 7-year follow-up time.
Ordinal logistics regression models were used to assess
the associations between baseline SUA and 7-year cognitive
trajectories. The final multivariable model was adjusted for
age, gender, marital status, education level, smoking status,
drinking status, BMI, depressive symptoms, CMD, and the
presence of prehypertension at baseline. We evaluated the dose–
response relationship between SUA, as a continuous change,
and each trajectory of cognitive function using restricted
cubic splines (RCS) with four knots (at the 5th, 35th, 65th,
and 95th percentiles). Then, subgroup analyses based on the
hyperuricemia status were performed. Considering the relatively
small sample size of the population with hyperuricemia
(N = 262), other subgroup analyses by the SUA levels were
conducted to test the robustness of the results. Participants
were divided into the high-level SUA and low-level SUA groups
based on the sex-specific median and 75th quartile of SUA.
Both continuous and categorical (sex-specific median of SUA in
each subgroup) types were constructed and used in subgroup
analyses (lower SUA level as a reference category).
Subsequently, we used multiple linear regression
models to explore the effect of changes in SUA on 3-year
cognitive change, adjusting for the same abovementioned
covariates and SUA in 2015. The regression coefficient
(β) and its 95% confidence interval (CI) were presented.
The cognitive change was calculated by differences in

Measurements of non-normotensive
status
Systolic blood pressure (SBP) and diastolic blood pressure
(DBP) were measured three times repeatedly by trained medical
staff using an Omron HEM-7200 Monitor. We used the average
of the three measured results as the final blood pressure. Past
medical history and medication history of hypertension were
obtained from self-reports.
The non-normotensive status included prehypertensive and
hypertensive statuses (Wu et al., 2021b). Hypertension status
was defined as SBP ≥ 140 mmHg or DBP ≥ 90 mmHg, the
use of anti-hypertensive medication, or self-reported history of
hypertension (Chobanian et al., 2003). Prehypertension status
was defined as SBP of 120–139 mmHg or DBP of 80–89 mmHg
(Chobanian et al., 2003).

Covariates
Several covariates were included in our analyses.
Sociodemographic characteristics included age, gender
(men and women), marital status (married and others), and
educational level (no formal education, junior high school
or below, and high school or above). Health-related lifestyles
included self-reported smoking status (non-smoker, former
smoker, and current smoker) and drinking status (drink more
than once a month, drink but less than once a month, and
none of these). Body mass index (BMI) was calculated as
weight in kilograms divided by height in meters squared and
was categorized as follows: < 18.5, 18.5–23.9, ≥24.0 (Wang
and Zhai, 2013). Depressive symptoms were assessed using
the 10-item Center for Epidemiological Studies Depression
Scale (CES-D-10). A score of ≥ 12 indicated the presence
of depressive symptoms (Chen and Mui, 2014). Self-reported
history of cardiometabolic diseases (CMD) included diabetes,
dyslipidemia, stroke, and heart-related diseases (Huang Z. T.
et al., 2022). We calculated the estimated glomerular filtration
rate (eGFR) using the Chronic Kidney Disease Epidemiology
Collaboration’s 2009 creatinine equation (Levey et al., 2009).
Finally, physical activity was assessed by the questionnaires
among a randomly selected subsample of the study population.
Physical activity was defined as ≥150 min/week of moderate,
or ≥ 75 min/week of vigorous activity, or a combination
(≥600 metabolic equivalents [METs]) (Lloyd-Jones et al., 2010;
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TABLE 1 Baseline characteristics of the study
population in two cohorts.

cognitive scores between 2015 and 2018: Cognitive changes =
cognitive score2018 − cognitive score2015 . RCS with four knots
was used to capture the dose–response relationship between
changes in SUA and cognitive changes.
Sensitivity analyses were also conducted as follows:
(1) eGFR was further adjusted to explore the stability
of our findings; (2) the models were further adjusted
for physical activity in the subpopulations of two study
cohorts who underwent physical activity assessments; (3)
the generalized estimating equation (GEE) models were
used to examine the longitudinal association between
the SUA levels and cognitive function in the following
several years; (4) the effect of baseline SUA on cognitive
trajectories in subgroups, according to age, gender, depression
status, and the presence of prehypertension and nonnormotensive combined with other CMD were analyzed;
(5) cognitive scores in 2018 were used as the secondary
outcome to explore the effect of changes in SUA on cognitive
function, adjusting for the abovementioned covariates plus
cognitive scores in 2015.
Group-based trajectory models and GBMTM techniques
were implemented using the Proc Traj in Stata software version
15.1. Other statistical analyses above were performed with the
R software version 4.1.0. A two-sided p-value < 0.05 was
considered statistically significant.

Characteristics

No. of participants

The first
cohort

The second
cohort

3905

2077

Age(years), mean (SD)

58.48 (8.54)

57.78 (8.06)

Male, n (%)

1968 (50.4)

1046 (50.4)

Married, n (%)

3383 (86.6)

1833 (88.3)

No formal education

1400 (35.9)

654 (31.5)

Junior high school or below

1997 (51.1)

1136 (54.7)

High school or above

508 (13.0)

287 (13.8)

Non-smoker

2309 (59.1)

1243 (59.8)

Former smoker

391 (10.0)

206 (9.9)

Current smoker

1205 (30.9)

628 (30.2)

1072 (27.5)

569 (27.4)

Educational level, n (%)

Smoking status, n (%)

Drinking status, n (%)
More than once a month
Less than once a month

312 (8.0)

177 (8.5)

None of these

2521 (64.6)

1331 (64.1)

Depressive symptoms, n (%)

875 (22.4)

504 (24.3)

BMI (kg/m2 ), n (%)
<18.5

160 (4.1)

81 (3.9)

18.5–23.9

1829 (46.8)

897 (43.2)

≥24.0

1916 (49.1)

1099 (52.9)

Diabetes

295 (7.6)

154 (7.4)

Dyslipidemia

510 (13.1)

273 (13.1)

CMD, n (%)

Results

Stroke

Baseline characteristics

Heart-related diseases

The mean age of the 3,905 participants was 58.48
± 8.54 years and 50.4% of participants were men. The mean
age of the 2,077 participants was 57.78 ± 8.06 years and
50.4% of participants were men. The distribution of baseline
SUA, changes in SUA, baseline covariates, and cognitive scores
is shown in Table 1.

31 (1.5)

559 (14.3)

295 (14.2)

At least 1 CMD, n (%)

1080 (27.7)

573 (27.6)

Prehypertension, n (%)

1596 (40.9)

1011 (48.7)

91.97 (14.86)

92.77 (14.43)

4.61 (1.29)

5.11 (1.41)

Global cognitive function

12.23 (3.50)

12.32 (3.57)

Executive function

8.45 (2.55)

8.54 (2.56)

Episodic memory

3.78 (1.67)

3.79 (1.67)

Changes in SUA

–

No hyperuricemia and increased SUA

–

1258 (60.6)

No hyperuricemia and decreased SUA

–

499 (24.0)

Incident hyperuricemia

–

199 (9.6)

Remittent hyperuricemia

–

50 (2.4)

Persistent hyperuricemia

–

71 (3.4)

Changes in SUA (mg/dL), mean (SD)

–

0.57 (1.10)

eGFR (mL/min/1.73 m2 ), mean (SD)
SUA (mg/dL), mean (SD)
Cognitive scores, mean (SD)

Estimated cognitive trajectories
Supplementary Table 1 shows the procedure of choosing
the optimal group number and shape parameter for the final
single-trajectory model. The BIC was lower for the model
with six trajectories (BIC = -33582.86). However, APP was
less than 0.7 for the two trajectories group. Additionally, the
average APP of all groups for the model with five trajectories
was less than with four trajectories. Thus, we determined four
single trajectories of global cognitive function reflected the
longitudinal change patterns over 7 years (Figure 1A): class
1, “low-declining” (n = 293, 7.50%); class 2, “moderate lowdeclining” (n = 769, 19.69%); class 3, “moderate high-stable”
(n = 1,472, 37.70%); and class 4, “high-stable” (n = 1,371,
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76 (1.9)

Data are presented as the mean (SD), median [IQR] or number (%), as appropriate. BMI,
body mass index; CMD, cardiometabolic diseases; eGFR, estimated glomerular filtration
rate; SUA, serum uric acid.

35.11%). The four groups represented a trend of increasingly
better cognitive trajectories.
Using the same criteria and procedure (Supplementary
Table 2), we determined four groups using GBMTM that

05

frontiersin.org

Wang et al.

10.3389/fnagi.2022.944341

FIGURE 1

Trajectories of cognitive function from 2011 to 2018 among non-normotensive populations. Graphs show four trajectories of global cognitive
function (A) and four multi-trajectories of executive function and episodic memory (B). Descriptions of the trajectory groups are as follow: (A)
group 1: “low-declining,” group 2: “moderate low-declining,” group 3: “moderate high-stable,” group 4: “high-stable”; (B) group 1: “episodic
memory: low-rapid declining + executive function: low-declining,” group 2: “episodic memory: low- minimal declining + executive function:
moderate-declining,” group 3: “episodic memory: moderate-stable + executive function: high-declining,” group 4: “episodic memory:
high–rising + executive function: high-stable.”

or J-shaped relationship with the risk of each poor cognitive
trajectory. As seen in Figure 2, the protective effect of SUA
disappeared when the SUA level was excessively higher.
In subgroup analyses based on SUA levels (Table 3), we
observed that the negative association of baseline SUA with
poorer global cognitive single-trajectories (OR: 0.890; 95%
CI: 0.834, 0.950) and worse cognitive multi-trajectories (OR:
0.911; 95% CI: 0.853, 0.973) remained statistically significant
among those without hyperuricemia. However, no significant
association was found among those with hyperuricemia.
Choosing different cut-points for SUA levels to perform other
subgroup analyses yielded similar results (sex-specific median or
75th percentile). Notably, among those with ≥ 75th percentile
level of SUA, higher SUA levels were positively correlated with
poor global cognitive trajectories (OR: 1.048; 95% CI: 0.821,
1.337). Although this result was not statistically significant,
it still suggested the adverse effect of higher SUA levels on
cognition among those with hyperuricemia.

showed the longitudinal joint changes of episodic memory
and executive function (Figure 1B): class 1, “episodic memory:
low-rapid declining + executive function: low-declining”
(n = 330, 8.45%); class 2, “episodic memory: low-minimal
declining + executive function: moderate-declining” (n = 882,
22.59%); class 3, “episodic memory: moderate-stable + executive
function: high-declining” (n = 1,728, 44.25%); class 4, “episodic
memory: high-rising + executive function: high-stable” (n = 965,
24.71%). The four groups also can represent a trend of
increasingly better cognitive multi-trajectories. The maximum
likelihood estimates for the final trajectory models are
summarized in Supplementary Tables 3, 4.

Associations between the baseline
serum uric acid and 7-year cognitive
trajectories
We found that higher baseline SUA levels had a lower risk
of poorer global cognitive single-trajectories in three adjusted
models (Table 2). The odds ratio (OR) of the highest SUA of
less optimal trajectories was 0.755 (95% CI: 0.634 - 0.900, P for
trend = 0.002) as compared with those with the lowest levels of
SUA after full adjustment of covariates in model 3. Similarly,
higher baseline SUA was negatively associated with worse and
declining memory and executive function multi-trajectories.
The OR was 0.940 (95% CI: 0.894, 0.990) for SUA per 1 mg/dL
increase in model 3. We used RCS to estimate the trend in the
risk for each poor trajectory relative to the best trajectory. The
spline function for SUA confirmed the non-linear, U-shaped,
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Associations between changes in
serum uric acid and 3-year cognitive
change
Table 4 shows the association between changes in SUA and
future 3-year cognitive change. Compared with participants in
the “non-hyperuricemia with elevated SUA” group, participants
in the “non-hyperuricemia with decreased SUA” group had a
higher risk for decline in global cognitive function (β: -0.387;
95% CI: -0.696, -0.078) and executive function (β: -0.335; 95%
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TABLE 2 Associations between baseline SUA and risk of poorer cognitive trajectories.

Model 1

Model 2

Model 3

OR (95% CI)

P-value

OR (95% CI)

P-value

OR (95% CI)

P-value

0.907 (0.865, 0.952)

<0.001

0.946 (0.899, 0.995)

0.032

0.948 (0.901, 0.998)

0.043

Global cognitive trajectories
SUA, +1 mg/dL
By sex-specific quartiles a
Q1

Ref.

Q2

0.829 (0.703, 0.977)

0.025

0.843 (0.710, 1.000)

Ref.
0.051

0.855 (0.720, 1.016)

0.076

Q3

0.773 (0.656, 0.911)

0.002

0.808 (0.680, 0.960)

0.015

0.821 (0.690, 0.977)

0.026

Q4

0.661 (0.560, 0.780)

<0.001

0.747 (0.628, 0.889)

0.001

0.755 (0.634, 0.900)

<0.001

P for trend

Ref.

0.001

0.002
0.002

Multi-trajectories
SUA, +1 mg/dL

0.904 (0.861, 0.948)

<0.001

0.938 (0.892, 0.987)

0.013

0.940 (0.894, 0.990)

0.018

By sex-specific quartiles a
Q1

Ref.

Q2

0.807 (0.684, 0.952)

0.011

0.809 (0.681, 0.961)

0.016

0.816 (0.687, 0.970)

0.021

Q3

0.732 (0.621, 0.864)

<0.001

0.748 (0.629, 0.889)

0.001

0.761 (0.639, 0.905)

0.002

Q4

0.691 (0.585, 0.815)

<0.001

0.777 (0.654, 0.924)

0.004

0.784 (0.659, 0.933)

0.006

P for trend

Ref.

<0.001

Ref.

0.002

0.004

CI, confidence interval; OR, Odds ratios; SUA, serum uric acid; ref., reference. Model 1: adjusted for age, gender. Model 2: adjusted for age, gender, marital status, education level, smoking
status, drinking status, depressive symptoms. Model 3: adjusted for age, gender, marital status, education level, smoking status, drinking status, depressive symptoms, BMI, diabetes,
dyslipidemia, stroke, heart-related diseases and prehypertension.
a The cutoff values were sex-specific quartiles of SUA (3.399, 4.008, and 4.733 mg/dL for women, 4.188, 4.964, and 5.818 mg/dL for men). Bold P-value denotes statistical
significance (P < 0.05).

significantly different between groups. The results did not
significantly change after further adjusting for physical
activity (Supplementary Table 8). Similarly, the SUA levels
were significantly negatively associated with worse cognitive
trajectories, especially in the non-hyperuricemia group and
the low-level SUA group. Conversely, higher SUA levels
were significantly positively associated with poorer cognitive
trajectories among the hyperuricemia group and the high-level
SUA group (75th percentile as cut-points). In the second
cohort, 872 participants with assessments of physical activity
were included. There was also no significant difference in
all variables between the included and excluded populations
(Supplementary Table 9). Only the Q4 group of changes
in SUA was related to improved global cognitive function
compared with the Q1 group (β: 0.629; 95% CI: 0.002, 1.255)
(Supplementary Table 10). However, the associations of
“non-hyperuricemia with decreased SUA” and “persistent
hyperuricemia” with cognitive changes became non-significant,
probably due to the reduced sample size.
Moreover, the associations between the SUA levels and
cognitive scores over time based on GEE models are shown
in Supplementary Table 11. With each 1 mg/dl increase of
SUA, the global cognitive score increased by 0.071 (95%CI:
0.015, 0.128) and the executive function score increased
by 0.077 (95%CI: 0.035, 0.118). Similarly, a protective role
for SUA was only found among those with normal or
lower SUA. Interestingly, it seems that higher SUA levels

CI: -0.555, -0.114). Additionally, the “persistent hyperuricemia”
group was negatively associated with improved global cognitive
function (β: -0.851; 95% CI: -1.562, -0.140) and enhanced
executive function (β: -0.672; 95% CI: -1.180, -0.164). The risk
of cognitive decline was higher in the persistent hyperuricemia
group. Both the remittent and incident hyperuricemia groups
were not significantly associated with cognitive decline.
When the changes in SUA were calculated as the difference
of both SUA measurements, only the Q3 group of change was
related to improved global cognitive function compared with the
Q1 group (β: 0.449; 95% CI: 0.073, 0.826). Moreover, there was
a non-linear relationship between changes in SUA and cognitive
change. The dose–response relationship indicated that moderate
increases in the level of SUA were beneficial to enhance cognitive
function (Figure 3).

Sensitivity analyses
First, we repeated the analyses after further adjusting for
eGFR. The results remained almost consistent, as seen in
Supplementary Tables 5, 6.
Second, we excluded 2,198 participants without information
on physical activity in the first cohort, and the comparison
of baseline characteristics between participants included
and those who were not included in this analysis is
shown in Supplementary Table 7. All variables were not
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FIGURE 2

Longitudinal dose-response relationship between baseline SUA levels and poorer cognitive trajectories. The curve was estimated by a restricted
cubic spline function with four knots. Solid lines indicate OR. The reference was set to 3.686 mg/dL (25th quantile). The shadow represents 95%
confidence intervals. (A) Longitudinal dose–response relationship between baseline SUA levels and low-declining global cognitive trajectory. (B)
Longitudinal dose–response relationship between baseline SUA levels and moderate low-declining global cognitive trajectory. (C) Longitudinal
dose–response relationship between baseline SUA levels and moderate high-stable global cognitive trajectory. (D) Longitudinal dose–response
relationship between baseline SUA levels and “episodic memory: low-rapid declining + executive function: low-declining” trajectory. (E)
Longitudinal dose–response relationship between baseline SUA levels and “episodic memory: low-minimal declining + executive function:
moderate-declining” trajectory. (F) Longitudinal dose–response relationship between baseline SUA levels and “episodic memory:
moderate-stable + executive function: high-declining” trajectory.

could significantly impair episodic memory function among
those with hyperuricemia [clinical diagnosis criteria for
hyperuricemia (Huang Y. et al., 2022), sex-specific median, and
75th percentile as cut-points].
In addition, the results of subgroup analyses are presented in
Supplementary Figure 4. The protective effects of SUA on better
cognitive trajectories were significant in all subgroups by age,
depression status, and the presence of prehypertension. Such
association was observed among women but not among men.
When non-normotensive patients were complicated by at least
1 CMD, the protective effect of SUA also disappeared.
Finally, the results were similar when the cognitive score in
2018 was used as the secondary outcome, which are shown in
Supplementary Table 12.

executive function and episodic memory were identified
in prehypertensive and hypertensive populations. We
demonstrated that higher baseline SUA levels were negatively
associated with a declining and poorer 7-year cognitive
performance trajectory in a non-normotensive population.
In subgroup analyses, the associations only existed among
those with normal or lower levels of SUA. Reciprocally, higher
baseline SUA may impair cognitive function among patients
with hyperuricemia. Additionally, 4-year changes in SUA
could influence future 3-year cognitive changes. Maintenance
of the normal SUA levels and decreased levels of SUA at
the same time can disrupt cognitive function. For patients
with hyperuricemia in 2011, when SUA levels decreased to
the normal range in 2015, no adverse effects on cognitive
performance were found. Reversely, the persistent presence
of hyperuricemia increased the risk of cognitive decline. In
summary, our findings confirm the neuroprotective effect of
SUA. However, under only the normal levels of SUA, moderate
increases in SUA can prevent a decline in cognitive function
among the non-normotensive population.

Discussion
In this cohort study, four single-trajectories of global
cognitive performance and four multi-trajectories of
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TABLE 3 Associations between baseline SUA and cognitive trajectories in subgroups by SUA levels.

Subgroups

Global cognitive trajectories

Multi-trajectories

OR (95% CI)

P-value

OR (95% CI)

P-value

0.890 (0.834, 0.950)

<0.001

0.911 (0.853, 0.973)

0.006

Cut-points: clinical diagnosis criteriaa
Non-hyperuricemia group
SUA, +1 mg/dL
Lower-level SUA (by sex-specific median)
Higher-level SUA

Ref.

Ref.

0.823 (0.721, 0.939)

0.004

0.856 (0.748, 0.979)

0.023

1.169 (0.875, 1.561)

0.289

1.194 (0.884, 1.615)

0.247

Hyperuricemia group
SUA, +1 mg/dL
Lower-level SUA (by sex-specific median)
Higher-level SUA

Ref.

Ref.

0.983 (0.531, 1.825)

0.956

1.235 (0.647, 2.366)

0.522

0.896 (0.774, 1.038)

0.144

0.838 (0.722, 0.973)

0.021

Cut-points: sex-specific medianb
Low-level SUA group
SUA, +1 mg/dL
Lower-level SUA (by sex-specific median)
Higher-level SUA

Ref.

Ref.

0.825 (0.697, 0.978)

0.026

0.825 (0.694, 0.981)

0.029

0.996 (0.907, 1.092)

0.927

1.005 (0.915, 1.104)

0.913

High-level SUA group
SUA, +1 mg/dL
Lower-level SUA (by sex-specific median)
Higher-level SUA

Ref.

Ref.

0.902 (0.760, 1.070)

0.238

1.023 (0.859, 1.218)

0.800

0.901 (0.821, 0.989)

0.028

0.870 (0.791, 0.957)

0.004

Cut-points: sex-specific 75th quantilec
Low-level SUA group
SUA, +1 mg/dL
Lower-level SUA (by sex-specific median)
Higher-level SUA

Ref.

Ref.

0.859 (0.748, 0.987)

0.032

0.851 (0.739, 0.980)

0.025

1.081 (0.938, 1.245)

0.279

0.983 (0.852, 1.134)

0.815

High-level SUA group
SUA, +1 mg/dL
Lower-level SUA (by sex-specific median)
Higher-level SUA

Ref.

Ref.

1.048 (0.821, 1.337)

0.707

0.900 (0.704, 1.151)

0.400

CI, confidence interval; OR, Odds ratios; SUA, serum uric acid; ref., reference. Adjusted for: age, gender, marital status, education level, smoking status, drinking status, depressive
symptoms, BMI, diabetes, dyslipidemia, stroke, heart-related diseases and prehypertension.
a The clinical diagnosis criteria for hyperuricemia were > 6.0 mg/dL for women and > 7.0 mg/dL for men.
b The sex-specific median of SUA were 4.008 mg/dL for women, 4.964 mg/dL for men.
c The sex-specific 75th percentile of SUA was 4.733 mg/dL for women, 5.818 mg/dL for men. Bold P-value denotes statistical significance (P < 0.05).

Based on our results, 27.19% of individuals with
prehypertension and hypertension had a significant trend
of decline in global cognitive function. Meanwhile, 31.04%
of non-normotensive populations had a marked decreasing
trend in both episodic memory and executive function. Nonnormotensive patients had a high risk of incident cognitive
decline. Then, we found that the non-normotensive population
with high levels of SUA still had more favorable 7-year cognitive
trajectories than those with low levels of SUA, which is
similar to previous studies in the general population (Wang
T. et al., 2017; Xiu et al., 2017; Scheepers et al., 2019; Chen
et al., 2021). One potential protection mechanism may be
the antioxidant effects of SUA (Tana et al., 2018). Oxidative
stress or low antioxidant levels in the brain may exert an
important role in the pathogenesis of cognitive impairment or
dementia, leading to free radical generation, lipid peroxidation,
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and mitochondrial dysfunction (Zhou et al., 2021). While
higher SUA could protect the blood-brain barrier against
oxidative stress (Tana et al., 2018). Moreover, patients with
congenital SUA disorder may have a genetic tendency to
cognitive dysfunction (Qiao et al., 2021). Then, hypouricemia
is often accompanied by poor nutritional status, which results
in cognitive impairment (Sanders et al., 2016; Zhou et al.,
2021). Thus, people with higher SUA levels would show better
cognitive performance.
However, the results of some previous studies are
contradictory. A study reported that higher levels of SUA
were associated with faster cognitive decline (Alam et al., 2020).
Another finding of a 12-year cohort study demonstrated that
high SUA levels may increase the risk of dementia, especially
vascular or mixed dementia (Latourte et al., 2018b). This
inconsistency could be explained by the included patient with
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TABLE 4 Associations between changes in SUA and 3-year cognitive changes.

Global cognitive function
β (95% CI)

Episodic memory

P

β (95% CI)

–0.387 (–0.696, –0.078)

0.014

Incident hyperuricemia

0.007 (–0.440, 0.454)

Remittent hyperuricemia
Persistent hyperuricemia

Non-hyperuricemia with elevated SUA
Non-hyperuricemia with decreased SUA

Executive function
P

β (95% CI)

–0.053 (–0.247, 0.142)

0.595

–0.335 (–0.555, –0.114)

0.976

0.035 (–0.246, 0.317)

0.806

–0.029 (–0.348, 0.291)

0.861

0.055 (–0.789, 0.900)

0.898

–0.074 (–0.606, 0.458)

0.785

0.129 (–0.474, 0.733)

0.674

–0.851 (–1.562, –0.140)

0.019

–0.179 (–0.626, 0.269)

0.434

–0.672 (–1.180, –0.164)

0.010

0.075 (–0.049, 0.199)

0.235

0.025 (–0.053, 0.103)

0.528

0.050 (–0.039, 0.138)

0.270

Ref.

Ref.

P

Ref.
0.003

Changes in SUAa
Changes in SUA, +1 mg/dL
By quartilesb
Q1

Ref.

Q2

–0.067 (–0.436, 0.303)

0.723

–0.094 (–0.327, 0.138)

Ref.
0.426

0.029 (–0.236, 0.293)

Ref.
0.832

Q3

0.449 (0.073, 0.826)

0.019

0.002 (–0.235, 0.239)

0.987

0.447 (0.178, 0.717)

0.001

Q4

0.375 (–0.006, 0.757)

0.054

0.089 (–0.152, 0.329)

0.470

0.287 (0.014, 0.560)

0.040

CI, confidence interval; β, regression coefficient; SUA, serum uric acid; ref., reference. Adjusted for: age, gender, marital status, education level, smoking status, drinking status, depressive
symptoms, BMI, diabetes, dyslipidemia, stroke, heart-related diseases, prehypertension, and SUA levels in 2015.
a Changes in SUA was also calculated as the SUA level in 2015 minus that at baseline in 2011.
b The cutoff values were quartiles of changes in SUA (−0.073, 0.492, 1.150). Bold P-value denotes statistical significance (P < 0.05).

FIGURE 3

Longitudinal dose-response relationship between changes in serum uric acid and cognitive changes. The curve was estimated by a restricted
cubic spline function with four knots. Solid lines indicate the regression coefficient. The reference was set to 0 mg/dL. The shadow represents
95% confidence intervals. (A) Longitudinal dose–response relationship between changes in serum uric acid and global cognitive changes. (B)
Longitudinal dose–response relationship between changes in serum uric acid and episodic memory changes. (C) Longitudinal dose–response
relationship between changes in serum uric acid and executive function changes.

hyperuricemia. Cardiometabolic disorders, inflammation,
vascular damage, and the pro-arteriosclerotic effect caused
by higher SUA levels may counteract its neuroprotective role,
resulting in cognitive decline and increasing the risk of vascular
dementia (Tana et al., 2018; Zhou et al., 2021; Huang Y. et al.,
2022). Thus, we performed several subgroup analyses with
different SUA levels. We found that the non-normotensive
population with higher SUA levels has more stable and better
cognitive trajectories only in non-hyperuricemia groups, which
is similar to one previous study (Chen et al., 2021). The sample
size of adults with hyperuricemia in both our study and of the
study of Chen et al. (2021) was relatively small. Considering
this limitation, subgroups were divided by different cut-points
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for SUA levels (sex-specific median and 75th percentile) and
similar results were obtained. The significant protective effect
of SUA on cognitive function was found only in low-level SUA
subgroups. Notably, among those with higher or abnormal
levels of SUA, SUA could impair their cognitive function,
especially memory function. The optimum cut-points of the
abnormal levels of SUA to balance the integrated prevention of
cognitive impairment and cardiovascular and cerebrovascular
diseases should be further explored. Besides, the dose–response
relationship test further confirmed our results.
In sensitivity analyses, the protective effect of SUA also
disappeared when non-normotensive patients were complicated
by at least 1 CMD, which could further verify our conjecture
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mentioned above. Additionally, the finding of this association
only in women, rather than in men, may be explained by
the higher risk of cerebrovascular disease in men and the
estrogen effects after menopause in women (Lee et al., 2021).
Some studies reported similar research conclusions (Scheepers
et al., 2019; Lee et al., 2021). Our findings suggested that the
neuroprotective role of SUA should be emphasized in female
patients with hypertension without other CMD.
Innovatively, we also provide evidence that the changes
in SUA can influence future cognitive performance. When
SUA was maintained at normal levels over a period of time,
decreased levels of SUA are strongly associated with worse
cognitive performance. However, the persistent presence of
hyperuricemia may result in more severe cognitive decline.
Additionally, we analyzed the changes in SUA as a continuous
variable and the dose–response relationship. We proved that
a moderate increase in SUA levels may improve cognitive
function, rather than an excessive increase. When SUA increased
to abnormal levels, the protective effect of SUA may disappear.
SUA appears to be a double-edged sword due to both
the harmful effect on patients with hypertension and the
neuroprotective role (Latourte et al., 2018a; Yang et al., 2021).
In clinical practice, it also remains unknown whether uratelowering therapy has adverse effects on cognitive performance,
which is of great concern (Singh, 2018; Latourte et al., 2021). To
a certain extent, our study could provide supporting evidence
that remittent hyperuricemia was not associated with cognitive
decline. Conversely, the risk for cognitive decline may be even
higher if left untreated or if higher SUA levels are not controlled.
Decreased SUA may result in poorer cognitive changes only
in those without hyperuricemia. Our findings provide some
inspiration for balancing the urate-lowering therapy against
the prevention of cognitive impairment or dementia. The
maintenance of normal SUA levels is a primary condition
to prevent cognitive impairment and dementia. Thus, the
treatment of hyperuricemia should still be a priority in daily life
and clinical practice for non-normotensive populations.

measures data, such as GEE or linear mixed models, only focus
on mean population trajectories (Li et al., 2020). However,
the conventional method, GEE, was also used to validate
the robustness of our results. Finally, the strengths of our
study also include the prospective cohort design and the
use of a large nationwide representative sample covering 28
provinces in China.
We acknowledge several limitations of this study. First, the
physical activity investigation was limited to a randomly selected
subgroup in the CHARLS study and had a large number of
missing values. In the sensitivity analysis, physical activity was
adjusted for only in the subpopulation with a small sample size.
Second, residual confounding factors were not fully controlled.
Dietary intake, nutrients, and urate-lowering medications were
also not incorporated in the final model due to the lack of
related data. Additionally, the assessment tool for cognition
performance used was relatively simple and limited. The cutoff
values of cognitive impairment of this test were lacking, but
the moderate-to-high validity of this cognitive test was reported
compared with the Mini-Mental State Examination (MMSE)
and the Clinical Dementia Rating Scale (CDR) (Meng et al.,
2019). Finally, more time point measurements of the SUA levels
need to be conducted to capture the longitudinal patterns of
SUA over a period more accurately.

Strengths and limitations

Data availability statement

First, our findings extend and refine evidence that higher
SUA levels within the normal range could still protect cognitive
functions in the prehypertensive and hypertensive populations.
Additionally, single-time point measures of SUA and changes
in SUA over time were all considered. Furthermore, our
study fully considered different situations among both patients
with non-hyperuricemia and hyperuricemia, which provides
specific guidance to balance urate-lowering therapy against
the prevention of cognitive impairment or dementia. The
other strength is the use of GBTM and GBMTM to identify
groups of individuals who experienced similar levels and
change patterns of cognitive functions over time (Li et al.,
2020), while the traditional statistical approaches for repeated

The raw data supporting the conclusions of this article will
be made available by the authors, without undue reservation.
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Conclusion
In brief, our findings indicate that baseline SUA and changes
in SUA can affect future cognitive trajectories or changes in a
non-normotensive population. The maintenance of normal SUA
levels and a moderate increase of SUA may be beneficial for
enhanced cognitive function. However, the persistent presence
of hyperuricemia may result in cognitive decline. Although the
neuroprotective role of high levels of SUA was confirmed in
our study, the maintenance of normal SUA levels is a primary
condition to prevent cognitive impairment and dementia.
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